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Metaplastic breast cancers (MBCs) are characterized by complex genomes, which seem to vary according to their histologic
subtype. TERT promoter hotspot mutations and gene amplification are rare in common forms of breast cancer, but present in a
subset of phyllodes tumors. Here, we sought to determine the frequency of genetic alterations affecting TERT in a cohort of
60 MBCs with distinct predominant metaplastic components (squamous, 23%; spindle, 27%; osseous, 8%; chondroid, 42%), and to
compare the repertoire of genetic alterations of MBCs according to the presence of TERT promoter hotspot mutations or gene
amplification. Forty-four MBCs were subjected to: whole-exome sequencing (WES; n= 27) or targeted sequencing of 341-468
cancer-related genes (n= 17); 16 MBCs were subjected to Sanger sequencing of the TERT promoter, TP53 and selected exons
of PIK3CA, HRAS, and BRAF. TERT promoter hotspot mutations (n= 9) and TERT gene amplification (n= 1) were found in 10 of
the 60 MBCs analyzed, respectively. These TERT alterations were less frequently found in MBCs with predominant chondroid
differentiation than in other MBC subtypes (p= 0.01, Fisher’s exact test) and were mutually exclusive with TP53 mutations (p <
0.001, CoMEt). In addition, a comparative analysis of the MBCs subjected to WES or targeted cancer gene sequencing (n= 44)
revealed that MBCs harboring TERT promoter hotspot mutations or gene amplification (n= 6) more frequently harbored PIK3CA
than TERT wild-type MBCs (n= 38; p= 0.001; Fisher’s exact test). In conclusion, TERT somatic genetic alterations are found in a
subset of TP53 wild-type MBCs with squamous/spindle differentiation, highlighting the genetic diversity of these cancers.
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INTRODUCTION
Metaplastic breast cancer (MBC) is a rare (0.2–1%)1,2, aggressive
histologic subtype of breast cancer, characterized histologically by
neoplastic epithelium displaying differentiation towards squa-
mous or mesenchymal elements, including spindle, chondroid,
osseous, or rhabdoid cells. MBCs can present one (monophasic) or
two or more (biphasic) components. These components can both
display metaplastic histology or can be one metaplastic compo-
nent and one adenocarcinoma component, which is most
commonly in the form of invasive ductal carcinoma of no special
type (IDC-NST). MBCs are most often of high histologic grade and
display a triple-negative phenotype1,3.
The histologic diversity of MBCs is associated with distinct
genomic and transcriptomic profiles4–12. From a genetic
standpoint, MBCs are shown to frequently harbor mutations
affecting TP53 and genes related to the PI3K/AKT/mTOR path-
ways. While TP53 mutations are found to be less frequent in
MBCs with prominent spindle cell component, PIK3CA mutations
are vanishingly rare in MBCs with chondroid metaplasia7,12,13.
The transcriptomic features of MBCs also vary according to the
predominant histologic component; for instance, MBCs with a
predominant spindle cell component are preferentially classified
as of claudin-low subtype, whereas MBCs with squamous or
chondroid metaplasia are more frequently classified as of basal-
like or even normal breast-like subtypes than as of claudin-low
subtype8,9.
Somatic TERT promoter mutations (C228T and C250T), asso-
ciated with telomerase activation, have been reported at a
relatively high frequency in human cancers (12% overall)14 and
are associated with disease progression and recurrences15–17.
Although thought to be absent or extremely rare in common
forms of breast cancer18–20, TERT promoter mutations and TERT
gene amplifications have been reported in up to 68% of
malignant phyllodes tumors of the breast, a potential differential
diagnosis of MBCs, and may have a role in the malignant
progression in fibroepithelial lesions15,21,22. TERT gene amplifica-
tion has been reported in 13% of adenomyoepitheliomas of the
breast, tumors of uncertain malignant potential which have been
reported to progress to spindle cell MBCs in a minority of
cases23,24. Interestingly, in one adenomyoepithelioma progres-
sing to a triple-negative spindle cell MBC, the submodal clone
that most likely gave rise to the invasive carcinoma harbored a
TERT promoter hotspot mutation24. In the context of MBCs, TERT
promoter hotspot mutations have been reported in up to 25% of
cases, and to be associated with MBCs with spindle and/or
squamous differentiation12.
Here, we sought to determine the frequency of genetic
alterations affecting TERT, including TERT promoter hotspot
mutations and TERT gene amplifications in MBCs with distinct
types of predominant metaplastic component (e.g. squamous,
spindle cell, osseous and chondroid). We have also compared the
repertoire of somatic genetic alterations of MBCs harboring TERT
promoter mutations or gene amplification to MBCs lacking genetic
alterations targeting TERT. These analyses have revealed that 17%
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(10 out of 60) of MBCs harbor TERT somatic genetic alterations,
and that these are associated with specific predominant




Sixty primary MBCs were included in this study (Table 1 and
Supplementary Table S1), including 4 biopsies and 56 resection
specimens; of these specimens, 6 (5 resections and 1 biopsy) were
obtained post neoadjuvant therapy. The median age at diagnosis
was 57 years old (range 34–85). Most (92%, 55/60) MBCs were of
histologic grade 3 and 95% (57/60) of the MBCs analyzed were of
triple-negative phenotype (Table 1). Upon central histopatholo-
gical review, the MBCs included in this study were classified
according to their predominant histologic type into squamous
(23%; 14/60), spindle cell (27%; 16/60), osseous (8%; 5/60), or
chondroid (42%, 25/60) MBCs (Fig. 1 and Supplementary Table
S1). Forty-seven percent (28/60) of the MBCs were matrix-
producing, including MBCs with predominant chondroid (n=
24) and osseous (n= 4; Table 1 and Supplementary Table S1)
histologic components.
TERT genetic alterations in MBCs
We first sought to determine the frequency of TERT genetic
alterations in 60 MBCs included in this study. Genetic alterations
affecting TERT were identified in 17% (10/60) of the MBCs,
including a recurrent hotspot mutation affecting the TERT
promoter hotspot locus (C228T; 15%, 9/60) and TERT gene
amplification (2%, 1/60; Fig. 2). All MBCs harboring TERT promoter
alterations were of triple-negative phenotype (Fig. 2). We next
performed a hypothesis-generating, exploratory analysis of the
associations between the presence of TERT somatic genetic
alterations and the phenotype of MBCs (Fig. 2 and Supplementary
Fig. S1). This analysis revealed that TERT genetic alterations were
significantly less frequently found in MBCs with a predominant
chondroid component (0/25) than in the remaining MBCs (10/35;
p= 0.005, Fisher’s exact test, Table 2 and Fig. 2). Nonetheless, two
of these 10 MBCs harboring TERT genetic alterations including a
predominant spindle cell MBC (MBC119T, TERT promoter muta-
tion) and a predominantly osseous MBC (MT82, TERT gene
amplification) displayed focal areas of chondroid differentiation
(Fig. 2).
Comparative analysis between TERT altered MBCs and TERT
wild-type MBCs
We next sought to define whether the six MBCs harboring TERT
gene promoter hotspot mutations or gene amplification displayed
a distinct repertoire of somatic genetic alterations as compared to
the 38 TERT wild-type MBCs (Fig. 3, Supplementary Table S2)
subjected to whole-exome sequencing (WES) or MSK-IMPACT
targeted sequencing of 341–468 cancer-related genes. In our
study, MBCs harboring TERT genetic alterations had a tumor
mutation burden (median 3.1 mutations/Mb; range 0.8–6.1)
comparable to that of MBCs lacking genetic alterations affecting
TERT (median 3.5 mutations/Mb; range 0.8–8.7; p= 0.72,
Mann–Whitney U test; Supplementary Fig. S2a). Our exploratory
analysis revealed that, despite having similar tumor mutation
burden, MBCs harboring TERT genetic alterations were signifi-
cantly enriched for PIK3CA clonal mutations preferentially affect-
ing hotspots (5/6, 83% TERT altered vs 5/38, 13% TERT WT; p=
0.001, Fisher’s exact test). Four of the 5 MBCs harbored clonal TERT
promoter hotspot mutations co-occurring with PIK3CA mutations,
and one MBC (MT45) that lacked mutations affecting PIK3CA
harbored a subclonal TERT promoter mutation (Fig. 3a and
Supplementary Fig. S3). TP53 mutations were significantly more
frequently detected in MBCs lacking genetic alterations affecting
TERT (34/38, 89% TERT wild-type vs 3/6, 50% TERT altered; p= 0.04,
Fisher’s exact test; Fig. 3a). A formal mutually exclusivity analysis
based on CoMEt25 in these 44 MBCs demonstrated that TP53
mutations were significantly mutually exclusive with TERT genetic
alterations (p < 0.01, CoMEt). This observation was further
confirmed when the entire cohort (n= 60) of MBCs was analyzed
(p < 0.001, CoMEt; Fig. 2).
Although no other gene was significantly differentially altered
between TERT altered vs wild-type MBCs (p > 0.05; Fisher’s exact
test, Fig. 3a), mutations affecting PTEN, PIK3R1, chromatin
Table 1. Clinicopathologic features of 60 metaplastic breast carcinomas included in this study.
Predominant histologic component
MBCs SQUAMOUS SPINDLE OSSEOUS CHONDROID
(n= 60) (n= 14) (n= 16) (n= 5) (n= 25)
Histologic gradea 2 5 (8%) 1 (7%) 1 (6%) 0 3 (12%)
3 55 (92%) 13 (93%) 15 (94%) 5 22 (88%)
Matrix producing No 32 (53%) 14 (100%) 16 (100%) 1 (20%) 1 (4%)
Yes 28 (47%) 0 0 4 (80%) 24 (96%)
ER status Negative 59 (98%) 13 (93%) 16 (100%) 5 (100%) 25 (100%)
Positive 0 0 0 0 0
Not available 1 (2%) 1 (7%) 0 0 0
PR status Negative 59 (98%) 13 (93%) 16 (100%) 5 (100%) 25 (100%)
Positive 0 0 0 0 0
Not available 1 (2%) 1 (7%) 0 0 0
HER2 status Negative 57 (95%) 11 (79%) 16 (100%) 5 (100%) 25 (100%)
Positive 2 (3%) 2 (14%) 0 0 0
Not available 1 (2%) 1 (7%) 0 0 0
Triple-negative phenotype n (%) 57 (95%) 11 (79%) 16 (100%) 5 (100%) 25 (100%)
ER, estrogen receptor; PR, progesterone receptor.
aNottingham grading system.
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Fig. 1 Histologic features of the metaplastic breast cancers included in this study. Representative hematoxylin-and-eosin
photomicrographs of metaplastic breast cancers (MBCs) with predominant a squamous cell carcinoma component (MBC103T), b spindle
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Fig. 2 Recurrent somatic TERT, TP53, PIK3CA, HRAS, and BRAF genetic alterations in distinct histologic subtypes of 60 metaplastic breast
cancers. Heatmap depicting the proportion of the histologic component, frequency of TERT genetic alterations, TP53 mutations, PIK3CA
mutations, HRASmutations and BRAF genetic alterations in 60 MBCs. Mutation types are color-coded according to the legend. Cases are shown
in columns, the percentage of the histological components, matrix producing, ER and HER2 status, and sequencing methods are depicted in
phenobars. *Mutual exclusivity analysis, CoMEt, p < 0.001.
Table 2. Frequency of genetic alterations affecting TERT gene in 60 metaplastic breast cancers according to their predominant histologic
component.
Predominant histologic component
MBCs SQUAMOUS SPINDLE OSSEOUS CHONDROID p valuea
(n= 60) (n= 14) (n= 16) (n= 5) (n= 25)
TERT genetic alteration 10 (17%) 3 (21%) 5 (31%) 2 (40%) 0 0.005
TERT wild-type 50 (83%) 11 (79%) 11 (69%) 3 (60%) 25 (50%)
aStatistical significance was evaluated by Fisher’s exact test.
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remodeling genes (ARID1A, KMT2C) and tumor suppressor genes
(RB1, NOTCH1, and NOTCH2) were only identified in MBCs lacking
TERT genetic alterations (Fig. 3a). In addition, activating mutations
affecting Ras pathway genes were detected in three MBCs
harboring TERT promoter hotspot mutations, including hotspot
mutations affecting KRAS (MTC01, subclonal A59G, n= 1), NRAS
(MT45, clonal Q61L, n= 1) and HRAS Q61R (MT35, clonal, n= 1),






























































































































































































































































Fig. 3 Repertoire of non-synonymous somatic mutations identified in metaplastic breast cancers. a Comparison of the most frequent
genetic alterations affecting cancer genes identified in metaplastic breast cancers harboring TERT genetic alterations (TERT promoter hotspot
mutations, n= 5; TERT gene amplification, n= 1; left) and TERT wild-type (n= 38, right), by whole-exome sequencing or MSK-IMPACT targeted
sequencing. Cases are shown in columns and genes in rows. Clinicopathologic characteristics are shown on the top. Mutations are color
coded according to the legend. Frequency plots and Fisher’s exact test comparison corrected for multiple testing of (b) copy number gains
and losses, and (c) amplifications and homozygous deletions between TERT altered (n= 6) and TERT promoter wild-type (n= 38) MBCs.
Frequency (y-axis) of gains and losses and amplifications and homozygous deletions is shown for each genomic region (x-axis). Inverse Log10
values of the two-sided Fisher’s exact test p-values are plotted according to the genomic region (lower panel). Gains and amplifications are
colored in green. Losses and homozygous deletions are colored in purple. *Statistical significance was evaluated by the Fisher’s exact test (p <
0.05). **Mutual exclusivity analysis was performed using combinations of mutually exclusive alterations (CoMEt, p < 0.01). HRD, homologous
recombination DNA repair defect; SNV, single nucleotide variants.
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and clonal E204Vfs*4) and a subclonal BRAF D594N hotspot
mutation (Fig. 3a; Supplementary Fig. S3). Two TERT wild-type
MBCs harbored BRAF amplification (MTC23 and MBC104T;
Fig. 3a). Similar observations were made when the 16 additional
MBCs were subjected to Sanger sequencing of HRAS and BRAF
hotspot loci (Fig. 2). This additional analysis revealed another
MBC (MBC113T) harboring an HRAS hotspot mutation (Q61K,
Fig. 2) co-occurring with a TP53 hotspot mutation (D281E) but did
not identify mutations affecting TERT promoter or PIK3CA
hotspot locus.
Given the previous observation that HRAS Q61R hotspot
mutations co-occurring with TERT promoter mutations were
preferentially found in adenomyoepitheliomas24, we sought to
define whether the MBCs harboring HRAS Q61 hotspot mutations
would be associated with or originate from adenomyoepithelio-
mas. Not surprisingly, the HRAS Q61 mutant MBCs identified in our
study lacked histologic features of adenomyoepithelioma, unlike
TNBCs originating from adenomyoepithelioma, which have been
shown to lack TP53 mutations and consistently harbor PIK3CA or
PIK3R1 mutations24. Upon re-review of the MBCs, including all
diagnostic slides available per case harboring HRAS Q61 muta-
tions, only one MBC (MBC103T; Supplementary Fig. S4) was found
to display features consistent with the presence of a breast
adenomyoepithelioma. This MBC contained a biphasic prolifera-
tion of epithelial and myoepithelial cells (Supplementary Fig. S4),
where the abluminal layer expressed p63 and calponin by
immunohistochemical analysis, consistent with a diagnosis of
MBC developing in the context of an adenomyoepithelioma.
Sanger sequencing analysis of this case revealed mutations
affecting TERT promoter (C228T) and PIK3CA hotspot locus
(H1047R), but no TP53 mutations or alterations in HRAS codon
Q61 (Fig. 2).
Here we demonstrate that, thirty-eight of the 44 MBCs
subjected to WES or MSK-IMPACT sequencing had sufficient
single nucleotide variants (SNVs) to infer accurate mutational
signature (Fig. 3a, Supplementary Table S1). Based on SigMA
analysis, an algorithm previously validated for the analysis of
formalin-fixed paraffin-embedded (FFPE) samples subjected to the
FDA-approved MSK-IMPACT sequencing assay, 23 MBCs (60%, 23/
38) displayed dominant COSMIC mutational signatures 3 and 8
(associated with homologous recombination DNA repair defect;
HRD; Supplementary Table S3)26,27. The aging signatures 1 and 5
were dominant in 34% (13/38) of MBCs, one case displayed a
dominant APOBEC signature 2 (3%, 1/38) and one harbored a
dominant signature 17 of unknown etiology (3%, 1/38). No
statistically significant differences were observed in the frequency
of mutational signatures between TERT altered and TERT wild-type
MBCs (p > 0.05; Fisher’s exact test; Fig. 3a; Supplementary Table
S3). MBCs harboring TERT genetic alterations (n= 5) displayed a
lower fraction of the genome altered (FGA, median 22%; 9–51%)
than MBCs lacking genetic alterations affecting TERT (median=
54%; range, 20–86%, p= 0.002, Mann–Whitney U test; Supple-
mentary Table S1 and Supplementary Fig. S2b). Nonetheless, the
patterns of gene copy number profiles of both groups were
comparable (Fig. 3b, c).
DISCUSSION
The genomic and transcriptomic diversity of MBCs has been
documented by our group and others4–11. In fact, the repertoire
of genetic alterations and transcriptomic features of MBCs appear
to vary according to the predominant metaplastic component,
consistent with the notion of likely genotypic–phenotypic
correlations in these cancers. Here we demonstrate that in
agreement with the results by Krings and Chen12 at variance with
other forms of triple-negative breast cancer, TERT promoter
hotspot mutations and gene amplification are found in sub-
stantial subset of MBCs (17%), and that these alterations are
less frequently found in MBCs with a predominant chondroid
component.
Previous studies7–9,12,13 have shown that TP53 and PIK3CA
genes are the two most frequently mutated known cancer genes
in MBC and that these mutations, however, vary in frequency
according to the predominant metaplastic component. Consistent
with previous observations7–9,13, the MBCs with predominant
chondroid metaplasia included in this study lacked mutations
affecting PIK3CA and Ras pathway genes, whereas TP53 mutations
were found to be less frequent in MBCs with predominant spindle
cell component compared to squamous and chondroid MBCs.
These findings support the notion that a subset of MBCs harboring
PIK3CA mutations may benefit from therapies targeting the PI3K/
AKT/mTOR pathway. Recent studies have investigated the
addition of PI3K/mTOR inhibitors to standard chemotherapy28–31,
and found that patients with PI3K pathway-altered advanced
triple-negative MBCs had significantly higher response rates when
treated with mTOR inhibitors (temsirolimus or everolimus) in
combination with liposomal doxorubicin and bevacizumab than
patients with MBCs lacking PI3K/mTOR pathway alterations31.
Given the enrichment of PIK3CA mutations in non-chondroid
MBCs, these findings have further implications for the targeted
treatment of specific histological subtypes of MBCs.
The TERT promoter hotspot mutations and TERT gene
amplification described here were inversely correlated with TP53
mutations in a subset of MBCs analyzed, and significantly
associated with PIK3CA hotspot mutations. It should be noted
that pathogenic mutations affecting TP53 and TERT promoter
hotspot mutations have also been found to be inversely correlated
in other cancer types16,32, whereas TERT promoter and PIK3CA
hotspot mutations have been shown to be mutually exclusive in
ovarian cancers33, but to co-occur in other cancer types34,35,
including breast cancer19. Whether these associations reflect
epistatic interactions between TERT, TP53, and PIK3CA or whether
they would result from the different prevalence of TERT alterations
in different subtypes of MBC warrant further investigation.
TERT promoter hotspot mutations and TERT gene amplification
have been reported in phyllodes tumors of the breast, suggesting
that these genetic alterations might be the drivers of the
progression from benign to malignant lesions in a subset of
patients15,22,36. In addition, we have previously demonstrated that
TERT somatic genetic alterations in 13% of breast adenomyoe-
pitheliomas and in the carcinomas originating in association with
or from these tumors24. The TERT promoter mutations detected in
the present study are the result of an exchange of a single
cytosine to a thymine at chromosome 5 base position 1,295,228
(C228T, c.-124 C > T), which results in a new binding motif for ETS
transcription factors and leads to an increased transcriptional
activity of the TERT promoter37,38. These mutations have been
shown to constitute a mechanism of upregulated telomerase and
to result in increased proliferative capacity and other oncogenic
properties39. The frequency of TERT somatic alterations (i.e. in 17%
of MBCs) reported here is consistent with that reported by Krings
and Chen12 (i.e. 25% of MBCs), who observed an enrichment of
TERT promoter mutations in MBCs with predominant spindle cell
and/or squamous components. In contrast to the observations by
Krings and Chen12, who reported the absence of TERT promoter
mutations in chondroid matrix-producing carcinomas, in our
study, TERT genetic alterations were identified in two cases
displaying minor areas of chondroid differentiation, including one
MBC with predominant spindle cell component and another MBC
with predominant osseous component. It is possible that these
discrepancies might be related to the fact that our series included
MBCs with mixed histologic subtypes, in contrast to Krings and
Chen12, who included only 3 MBCs with mixed components. Of
these 3 cases, two had only one of the components (osseous)
subjected to sequencing. The remaining cases included in their
study12 were categorized as pure matrix-producing, spindle,
E.M. da Silva et al.
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squamous, or spindle/squamous MBCs that did not display
differentiation along other metaplastic lineages.
The observations reported here as well as those made by
others12 have diagnostic and taxonomic implications. First, given
that TERT promoter hotspot mutations and gene amplification can
also be found in MBCs, their detection should be used with
caution in the differential diagnosis between MBC and malignant
phyllodes tumor of the breast. Second, TERT and HRAS mutations
have been shown to be vanishingly rare in primary breast cancers,
including those of triple-negative phenotype; however, these
alterations can be found in adenomyoepitheliomas and in a
subset of MBCs, suggesting a tantalizing hypothesis that a subset
of MBCs may evolve through similar genetic pathways or be
etiologically related to adenomyoepithelial tumors. Further studies
to investigate whether a subset of MBCs may constitute malignant
myoepithelial tumors are warranted.
Our study has important limitations. Given the rarity of these
tumors, the small sample size of the study and the limited
amounts of DNA available for sequencing analysis in some cases,
not all samples could be subjected to WES or MSK-IMPACT
sequencing. Due to this limitation, our estimation of the frequency
of TERT gene amplification is conservative as we cannot rule out
the presence of TERT gene amplification in the 12 of the 16 MBCs
subjected to Sanger sequencing that were TERT wild-type. Second,
despite the multi-institutional cohort included in this study, we
currently cannot define whether the mutually exclusive nature of
TERT somatic genetic alterations and TP53 mutations in MBCs are
derived from epistatic interactions between these genes in the
context of MBC or if this mutual exclusivity is solely the result of
the different frequencies of alterations affecting these genes in
MBCs with distinct types of predominant metaplastic components.
Hence, these observations should be interpreted with caution and
warrant further investigation in larger series of MBCs. Furthermore,
the multi-institutional nature of our study precludes a definitive
survival analysis due to the lack of clinical follow-up information in
a large subset of cases in this series. Further studies to assess
survival correlations with TERT genetic alterations in MBCs patients
are warranted. Despite these limitations, our study provides
evidence suggesting that TERT genetic alterations may play a role
in MBCs and that these are likely associated with specific subsets




Following approval by the Institutional Review Board (IRB) of Memorial
Sloan Kettering Cancer Center (MSKCC), a retrospective series of 60 primary
MBCs was selected to be included in this study. Patient consents were
obtained according to the approved IRB protocol. Cases were reviewed by
at least two of four pathologists (MV, FP, HZ, and/or JSR-F) following the
criteria put forward by the World Health Organization3. Clinicopathologic
characteristics, including age, tumor size and hormone-receptor status,
were retrieved from the medical records (Supplementary Table S1). Tumors
were graded according to the Nottingham grading system40. The tumor
cell content and composition of the metaplastic elements were estimated
(i.e., squamous cell, spindle cell, chondroid and osseous) and in each case,
the metaplastic component most abundantly present was defined as
described8 (Supplementary Table S1). All samples were anonymized prior
to tissue processing.
Tissue preparation and DNA extraction
Ten-to-15 8-µm-thick sections from representative formalin-fixed paraffin
embedded (FFPE) tumor and matched normal tissue blocks of 21 MBCs
(21/60) were stained with nuclear fast red and microdissected using a
sterile needle under a stereomicroscope (Olympus SZ61) to ensure a tumor
content >80%, as previously described41. Genomic DNA was extracted
from tumor and matched normal tissues using the DNeasy Blood and
Tissue Kit (Qiagen) according to manufacturers’ instructions.
Whole-exome sequencing and MSK-IMPACT sequencing
Out of 60 MBCs included in our cohort, 44 (73%) were subjected to WES
(n= 27) or to massively parallel sequencing targeting all coding regions of
341 to 468 cancer-related genes using the FDA-approved MSK Integrated
Mutation Profiling of Actionable Cancer Targets assay (MSK-IMPACT, n=
17, Supplementary Table S2)42. Of the 27 MBCs subjected to WES, five
MBCs were microdissected and subjected to WES at MSK’s Integrated
Genomics Operations (IGO) using validated protocols, as previously
described7,43, and for 22 MBCs the raw sequencing data (FASTQ files)
reported in Ng et al.7 were retrieved and reanalyzed (see below). Of the 17
MBCs subjected to MSK-IMPACT sequencing, three were previously
reported in Zehir et al.14. Hence, in this manuscript, we include massively
parallel sequencing data from 19 previously unreported MBCs (5 subjected
to WES and 14 to targeted MSK-IMPACT sequencing) as well as Sanger
sequencing data from 16 previously unreported MBCs (see below). WES
and MSK-IMPACT sequencing data were processed using our validated
bioinformatics pipeline16,43,44. In brief, sequence reads were aligned to the
reference human genome GRCh37 using the Burrows-Wheeler Aligner
(BWA v0.7.15)45. Somatic single nucleotide variants (SNVs) were detected
with MuTect (v1.0)46. Insertion and deletions (indels) were detected using
Strelka (v2.0.15)47, VarScan2 (v2.3.7)48, Platypus (v0.8.1)49, Lancet (v1.0.0)50,
and Scalpel (v0.5.3)51. Cancer cell fractions (CCFs) of each somatic mutation
were computed using ABSOLUTE (v1.0.6)52, as previously described43,53.
Copy number alterations (CNAs) and loss of heterozygosity were
determined using FACETS54. Somatic mutations in tumor suppressor
genes that were deleterious/loss-of-function or targeting a mutational
hotspot in oncogenes were considered pathogenic. Mutations targeting
hotspot loci were annotated using cancerhotspots.org55. Mutational
signatures were defined using Signature Multivariate Analysis (SigMA)
tool56, for cases with at least 5 SNVs, as previously described57. Exposure-
based dominant mutational signatures obtained by SigMA56 (Supplemen-
tary Table S3) were comparable to the mutational signatures reported by
Ng et al.7, which were inferred using DeconstructSigs58, in 68% (15/22) of
the MBCs.
Tumour mutation burden (TMB) was calculated as the total number of
non-synonymous mutations divided by the number of bases analyzed, per
megabase. The fraction of genome altered (FGA) was defined as the
cumulative size of copy number segments which are not copy neutral
divided by the cumulative size of all copy number segments, as previously
described14,59.
As part of an exploratory, hypothesis generating analysis, the repertoire
of non-synonymous somatic mutations, mutational frequencies, and copy
number alterations of MBCs harboring TERT somatic genetic alterations,
including promoter mutations and gene amplification, were compared to
MBCs lacking TERT genetic alterations. For the comparative analyses of the
repertoire of non-synonymous somatic mutations, mutational frequencies,
and copy number alterations of MBCs subjected to either WES or MSK-
IMPACT, genes were restricted to the 341 genes included in MSK-IMPACT.
Assessment of somatic mutations by Sanger sequencing
We conducted the assessment of TERT promoter hotspot loci, TP53 (exons
2 to 11), PIK3CA (exons 9 and 20), HRAS (exon 3), and BRAF (exons 11 and
15) hotspot mutations in 16 MBCs with insufficient DNA yield by Sanger
sequencing. In addition, as TERT promoter region is usually poorly covered
by exome sequencing, TERT promoter hotspot mutations were assessed by
Sanger sequencing in the 27 MBCs subjected to WES. PCR amplification of
the selected genes was performed using the AmpliTaq Gold 360 Master
Mix kit (Life Technologies, ThermoFisher Scientific) using previously
described primers16,24,60 (Supplementary Table S4). PCR fragments were
cleaned using ExoSAP It (ThermoFisher Scientific) and Sanger sequenced
as previously described15,16.
Statistical analysis
Fisher’s exact test and Chi-Square test were used for comparison of
categorical variables, and Mann–Whitney U test for continuous variables.
All tests were two-tailed and p values <0.05 were considered statistically
significant. A mutual exclusivity analysis was performed using combina-
tions of mutually exclusive alterations (CoMEt) with the use of a pair-wise
Fisher’s exact test to detect the presence of significant pairs of genes25.
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
“The data generated and analysed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.1416048261. The whole-exome
sequencing data supporting Figs. 2, 3, Supplementary Figs. S2 and S3, and
Supplementary Tables S1, S2, and S3 are openly available in the Sequence Read
Archive via the following accession: https://identifiers.org/ncbi/insdc.sra:
SRP07369262. These data were first described in the original publication by Ng
et al.7 MSK-IMPACT sequencing data of 3 samples included in the MSK-IMPACT
Clinical Sequencing Cohort supporting Figs. 2, 3, Supplementary Figs. S2, S3, and
Supplementary Tables S1 and S2 are publicly available at cBioPortal (https://
identifiers.org/cbioportal:msk_impact_201763). These data were first described in the
original publication by Zehir et al.14 Sequencing data of 19 previously unreported
MBCs (5 subjected to whole-exome sequencing and 14 to MSK-IMPACT sequencing)
are available at cBioPortal (https://identifiers.org/cbioportal:mbc_msk_202164). Addi-
tionally, the following data are available upon request from the corresponding
authors: Histologic images supporting Fig. 1 and Supplementary Fig. S1; Sanger
sequencing electropherograms supporting Fig. 2, Table 2, and Supplementary Figs.
S1 and S4; Clinicopathologic data supporting Figs. 2 and 3, Table 1, and
Supplementary Table S1.”
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